Branded Legacy Invests Heavily in Innovation and Growth with $540,000 Expansion

Branded Legacy, Inc (OTC-PINK: BLEG), a prominent player in the biotech industry, proudly announces a substantial investment aimed at expanding its production capabilities and elevating its product offerings. This strategic initiative underscores Branded Legacy’s unwavering commitment to innovation, quality, and customer satisfaction. The expansion project is set to infuse over $500,000 worth of inventory into the company, reinforcing its position as a leader in the market.

The investment encompasses several key areas:

1. Raw Materials and Precursors: Branded Legacy Inc. has allocated $25,000 towards the procurement of top-quality raw materials and precursors. This financial commitment ensures that the company maintains the highest standards in its product formulations.

2. Hardware Purchases: In a dedicated effort to remain at the forefront of technological advancements, Branded Legacy has invested $10,000 in state-of-the-art hardware. This strategic move not only enhances production efficiency but also exemplifies the company’s dedication to staying ahead in the industry.

3. Inventory Expansion –

Preloaded Carts with Batteries: Branded Legacy Inc. has acquired the hardware and raw materials necessary to manufacture 2,500 preloaded carts with batteries, boasting a total estimated value of $105,000. These preloaded carts are designed to provide customers with a convenient and high-quality vaping experience.

510 Cartridges: The company has also made a significant investment in the production of 2,500 510 cartridges, with a total value of $75,000. These cartridges are renowned for their exceptional performance and compatibility with various vaping devices.

Tinctures: Branded Legacy is expanding its tincture production capacity by procuring the resources to manufacture 10,000 15-30 ml tinctures, with an estimated value of $400,000. These tinctures offer a versatile and potent solution for those seeking the benefits of cannabinoids in their daily lives.

Formulated Products: In addition to the ready-to-sell inventory, Branded Legacy Inc. has earmarked $100,000 in raw materials to fulfill various product orders as needed. These products are poised to set new standards in the industry, catering to the evolving needs of consumers.

This significant investment not only bolsters Branded Legacy’s market position but also underscores its unwavering commitment to providing premium-quality products to its valued customers. With a steadfast focus on innovation and excellence, Branded Legacy Inc. remains a trusted and pioneering name in the cannabis and wellness industry.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”